WO2000077227A1 - Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique - Google Patents

Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique Download PDF

Info

Publication number
WO2000077227A1
WO2000077227A1 PCT/US1999/013508 US9913508W WO0077227A1 WO 2000077227 A1 WO2000077227 A1 WO 2000077227A1 US 9913508 W US9913508 W US 9913508W WO 0077227 A1 WO0077227 A1 WO 0077227A1
Authority
WO
WIPO (PCT)
Prior art keywords
fibrin
nucleic acid
cell
tissue
cells
Prior art date
Application number
PCT/US1999/013508
Other languages
English (en)
Inventor
Stewart A. Cederholm-Williams
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to PCT/US1999/013508 priority Critical patent/WO2000077227A1/fr
Priority to JP2001503669A priority patent/JP2003502047A/ja
Priority to EP99935322A priority patent/EP1208212A4/fr
Priority to CA002375346A priority patent/CA2375346A1/fr
Publication of WO2000077227A1 publication Critical patent/WO2000077227A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This application relates to the use of fibrin polymers as vehicles for delivering genetic material to a cell or tissue.
  • Fibrin sealants are used to create solid formulations of polymerized fibrin or other fibrin-related molecules.
  • the form of the polymerization is typically initially the formation of stabile non-covalent associations between the fibrin molecules.
  • the non-covalent associations are supplemented by subsequent covalent cross-links that form due to the action of activated Factor XIII.
  • These solid formulations are often used to stop or reduce fluid leakage after injury, such as air leakage from the lung or blood leakage.
  • fibrin sealant overcomes concerns with the safety of blood products and the enzymes typically used to convert fibrinogen to a form capable of polymerization by using recombinant or autologous fibrinogen and keeping snake-derived converting enzymes well segregated from the step at which the sealant is applied to a patient.
  • recombinant or autologous fibrinogen and keeping snake-derived converting enzymes well segregated from the step at which the sealant is applied to a patient.
  • Autologous fibrinogen is practical through the technology of Edwardson et al., since preparation of the sealant is conducted within minutes from a small volume of blood; and segregation of the converting enzymes is possible by stabilizing the fibrin in soluble form while affinity binding techniques are used to segregate the enzymes away from the sealant.
  • nucleic acid construct that expresses an antisense RNA to interfere in the expression of a certain mRNA or one or more constructs that express two complementary strands designed to interfere in the expression of a certain mRNA.
  • nucleic acid-based vaccines seek to induce a percentage of cells to produce immune-reaction inducing polypeptides, to induce an antibody-based or cellular-based immune response.
  • tissue specificity can be provided by the cell surface markers utilized by the virus to gain entry into the cells.
  • this avenue is only helpful where a virus that targets a given tissue exists and can be practically utilized as a vector.
  • viral vectors are known to be favorable for gene therapy, such as the adenovirus, their preferred cellular targeting mechanism may not be appropriate for the desired target cell types.
  • further tools are needed to help increase specificity for the desired target cell type, and to overcome vector preferences for alternative cell targets.
  • compositions of fibrin sealants that incorporate recombinant vectors for delivery to a tissue or cell against which the sealant will be polymerized and, typically, adhered.
  • the vectors can be maintained at a locally at high concentration in the solid gel produced by the sealant, thereby increasing the efficiency of transfection or transformation of cells.
  • the fibrin gel is tolerant of a number of agents used as adjuvants in the transfection or transformation of cells.
  • Such fibrin sealant compositions can be used to deliver vectors to cells or tissues, whether or not the sought for transfection or transformation is in connection with traditional concepts of gene therapy.
  • the method can be used, for example, to create cells, such as plant cells, that produce a desirable product (such as a protein or a small molecule produced as a result of the transforming event).
  • the invention provides a method of transforming a cell comprising the steps of: applying a transformation effective amount of a nucleic acid to the cell; applying a fibrin gel to the cell so as to entrap a transformation effective amount of the nucleic acid; and transforming the cell with the nucleic acid.
  • the nucleic acid is applied in admixture with a fibrin or fibrinogen composition that forms the fibrin gel.
  • the invention provides a method of conducting gene therapy comprising: conducting the steps outlined above; and implanting the transformed cells into an animal.
  • the cell to which the nucleic acid is applied is a precursor of a more specialized cell type, and the method further comprises: maturing the cell to the specialized cell type either in vitro or in vivo following the implanting.
  • the invention provides a method of conducting gene therapy comprising the steps of: applying a transformation effective amount of a gene therapy effective nucleic acid to a tissue; applying a fibrin gel to the tissue so as to entrap a transformation effective amount of the nucleic acid; and transforming cells of the tissue with the nucleic acid.
  • the method further comprises: surgically exposing the tissue to allow for the applying steps.
  • the invention provides a method of conducting surgery on an animal comprising: surgically exposing an internal tissue; applying a transformation effective amount of a nucleic acid to a tissue; applying a fibrin gel to the tissue so as to entrap a transformation effective amount of the nucleic acid; and transforming cells of the tissue with the nucleic acid, wherein the nucleic acid encodes antigens or contains peptides that induce an antibody or cytotoxic T lymphocyte response to infection by a pathogenic microbe.
  • the nucleic acid encodes antigens or contains peptides that induce an antibody or cytotoxic T lymphocyte response to infection by a pathogenic microbe that is a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebacterium, Mycobacterium, Neisseria, Haemophilus, Actinomycetes, Streptomycetes, Nocardia, Enter obacter, Yersinia, Fancisella, Pasturella, Moraxella, Acinetobacter, Eiysipelothrix, Branhamella, Actinobacillus, Streptobacillus, Listeria, Calymmatobacterium, Brucella, Bacillus, Clostridium, Treponema, Escherichia, Salmonella, Kleibsiella, Vibrio, Proteus, Erwinia, Borrelia, Leptospira, Spirillum, Campylobacter, Shigella,
  • the invention provides a kit comprising: (a) a first composition for forming a fibrin gel comprising one of (i) fibrin monomer, (ii) fibrinogen or another fibrin precursor or (ii) a fibrin-analog; (b) a second composition for forming a fibrin gel comprising (1), where the first composition is pursuant to (i), an agent that reverses the conditions which stabilize fibrin as the monomer, (2), where the first composition is pursuant to (ii). an agent that converts the fibrinogen or fibrin-precursor to fibrin or (3).
  • the first composition is pursuant to (iii), a fibrin-related molecule that forms a gel with the fibrin-analog; and (c) composed separately in a third composition or incorporated into the first or second composition, a gene therapy effective amount of nucleic acid, wherein the fibrin gel formed of the first and second compositions is effective to entrap the nucleic acid in the vicinity of a cell or tissue.
  • the nucleic acid is composed with a separate adjuvant for increasing the efficacy with which the nucleic acid transforms or transfects cells.
  • the invention provides a method of conducting gene therapy comprising: transforming or transfecting cells with a nucleic acid to create recombinant cells; implanting the recombinant cells into an animal; and applying a fibrin gel to entrap recombinant cells at a desired location within the animal.
  • the method further comprises: surgically exposing the tissue to allow for the implanting and applying steps.
  • Clot formation in humans occurs by means of a complex cascade of reactions with the final steps being the conversion of fibrinogen by thrombin, calcium ions and activated Factor XIII to form ultimately cross-linked fibrin II polymer, alternatively known as insoluble fibrin II polymer, which is the insoluble fibrin clot.
  • Fibrinogen represents about 2 to 4 grams/liter of the blood plasma protein and is a complex protein consisting of three pairs of disulfide-linked polypeptide chains designated (A ⁇ ) 2 , (B ⁇ ) 2 , and ⁇ 2 .
  • a and B represent two small amino terminal peptides, known as fibrinopeptide A and fibrinopeptide B, respectively.
  • the six polypeptide chains of fibrinogen are folded into at least three globular domains in a linear disposition, two terminal "D-domains" and a central "E-domain".
  • the E-domain is believed to contain all six N-terminal residues of the polypeptide chains in fibrinogen molecule.
  • Each D-domain contains the C-terminal sequence from one ⁇ -chain, one ⁇ -chain.
  • insoluble fibrin clots e.g., cross-linked fibrin II polymer
  • fibrinogen being converted by thrombin to fibrin I monomer.
  • This conversion involves thrombin-mediated cleavage of the 16 a ino acid fibrinopeptide A (G1-R16) from each the two A ⁇ -chains of fibrinogen, producing two ⁇ -chains each with a new N-terminal having the amino acid sequence G17-P-R-V20-.
  • the fibrin I monomer can spontaneously polymerize with other fibrin I or fibrin II monomers due to intermolecular interactions (i.e., non-covalent bonds) between the E-domain of the converted fibrin monomer, which now has accessible non-covalent bonding sites, and a D-domain of a different fibrin I or fibrin II monomer.
  • Each D-domain of a fibrin monomer carries a polymerization site capable of stably interacting with an E-domain of a fibrin I or fibrin II monomer.
  • fibrin I monomer contacts between the two E-domain polymerization sites of one fibrin I monomer with two complementary D-domain polymerization sites, each from two different fibrin I monomers, are believed to result in linear fibrin fibrils (i.e., polymers) with half staggered overlapping molecular contacts.
  • the fibrin I polymer so formed is sometimes referred to as soluble fibrin I polymer because, by treatment with appropriate chemical means, the fibrin I polymer can be depolymerized and reconverted to fibrin I monomers.
  • the next step in the formation of fibrin clots involves the conversion of fibrin I monomer to fibrin II monomer.
  • This step involves the thrombin-mediated cleavage of the fibrinopeptide B from each of the two B ⁇ -chains of fibrin I.
  • the removal of the 14 amino acid fibrinopeptide B produces ⁇ -chains, each having a N-terminal sequence of G-H-R-.
  • Fibrin II monomers like fibrin I monomers, can spontaneously polymerize with other fibrin II or fibrin I monomers due to intermolecular interaction sites in the E- domain of one fibrin II monomer, which are made accessible by the cleavage reaction, with the D-domain of another fibrin II or fibrin I monomer.
  • fibrin II polymer is also sometimes referred to as soluble fibrin II polymer because by use of appropriate chemical treatments it can be depolymerized and reconverted to fibrin II monomers.
  • the exposure of the ⁇ -chain N-terminal sequences in the E-domain is important to fibrin clot formation as it facilitates covalent crosslinking by activated Factor XIII of adjacent fibrin II monomers in the fibrin II polymer.
  • activated Factor XIII is also capable of crosslinking fibrin I monomers in a fibrin polymer, the reaction is less efficient due to the presence of fibrinopeptide B on fibrin I.
  • Cross-linked fibrin II polymer is sometimes referred to as insoluble fibrin II polymer because it cannot be depolymerized and reconverted to fibrin II monomers .
  • calcium ions are believed to be important in the formation of fibrin clots and have a number of important roles. Calcium ions are believed necessary for the activation of prothrombin to thrombin, and since thrombin activates Factor XIII, calcium ions are indirectly necessary for Factor XIII activation. Further, active Factor XIII is believed to be a calcium-dependent enzyme that cannot cross-link fibrin polymers in the absence of calcium ions. Calcium ions also directly bind to polymeric fibrin and change the opacity and mechanical properties of the fibrin polymeric strands. For reviews of the mechanism of blood coagulation and the components of a fibrin clot, see CM. Jackson, Ann. Rev. Biochem., 49:765-81 1, 1980, and B. Furie and B.C. Furie, Cell, 53:505-518, 1988.
  • Fibrin Sealants A fibrin sealant is a biological adhesive whose effects imitate the stages of coagulation to form a fibrin polymer.
  • the sealant can be designed so that the fibrin monomer will be converted to insoluble fibrin polymer.
  • One type of fibrin sealant uses fibrinogen and consists of two components.
  • One component comprises concentrated human fibrinogen, bovine aprotinin and Factor XIII.
  • the second component comprises calcium chloride and an enzyme, such as thrombin, that converts fibrinogen to fibrin.
  • the fibrinogen component of this type of fibrin sealant is typically prepared from pooled human plasma.
  • the fibrinogen can be concentrated from the human plasma by cryoprecipitation and precipitation using various reagents, e.g., poly(ethylene glycol), diethyl ether, ethanol, ammonium sulfate or glycine.
  • various reagents e.g., poly(ethylene glycol), diethyl ether, ethanol, ammonium sulfate or glycine.
  • a second, newer type of fibrin sealant uses compositions consisting primarily of fibrin I or fibrin II monomers. See European Patent Application No. 0 592 242, published April, 1994. In these types of sealants, fibrin I monomers or fibrin II monomers or desBB fibrin monomers are prepared in advance of sealant application from fibrinogen using an appropriate proteolytic enzyme, such as thrombin or batroxobin.
  • the fibrin monomers are maintained in soluble form using an appropriate buffer.
  • Useful buffers include those that have a low pH or a chaotropic agent.
  • the fibrin I monomers, fibrin II monomers or desBB fibrin monomers in such solutions can be converted to fibrin polymers by mixing the solution with a second solution to produce a mixture with conditions that permit the spontaneous polymerization of the fibrin monomers to form a fibrin clot.
  • Fibrin I, fibrin II and desBB fibrin monomer-based sealants have several advantages over fibrinogen-based sealants.
  • fibrin monomer-based sealants do not include bovine or human thrombin.
  • the use of such sealants when the fibrin monomer is prepared from the autologous source (i.e., the patients themselves), introduces no foreign proteins into the recipient and thereby avoids complications arising from immunological reactions and risk of blood-borne infections.
  • the fibrin monomer- based sealants can be conveniently prepared. Soluble fibrin polymer can be dissolved using a weak acidic solution. In some embodiments, the resulting fibrin monomers are lyophilized to fine powders.
  • Such powders can easily be re-dissolved in a weak acid and induced to re-polymerize by the addition of an alkali buffer.
  • the powdered fibrin monomers can be dissolved in a chaotropic solution, e.g., urea, to a high concentration (> 150 mg/ml) and induced to re-polymerize by the addition of water.
  • a further advantage of fibrin monomer-based sealants is that as they generally use autologous components, their use poses a lower risk of exposure to blood-transmitted infectious agents such as hepatitis (including hepatitis B, and non-A, non-B hepatitis) and acquired immune deficiency virus (AIDS). See L.E.
  • bovine thrombin is a potent antigen, which can cause adverse immunological reactions in humans.
  • Bovine thrombin is a potent antigen, which can cause adverse immunological reactions in humans.
  • Each of the three different polypeptide chains (A ⁇ , B ⁇ and ⁇ ) of fibrinogen is coded by a separate gene.
  • the cD ⁇ As for each of these chains have been prepared (Chung et al., Ann. N Y. Acad. Sci. 408:449-456, 1983; Rixen et al., Biochemistry 22:3237-3244, 1983; Chung et al., Biochemistry 22:3244-3250, 1983; Chung et al., Biochemistry 22:3250-3256, 1983) and expressed in prokaryotic organisms.
  • each human fibrinogen chain has been introduced separately (Huang et al., J. Biol. Chem.
  • the individually expressed chains show antigenic similarities with fibrinogen and display thrombin cleavable sites similar to those found in native fibrinogen (Bolyard and Lord, Blood, 73: 1202-1206, 1989; Lord and Fowlkes, Blood. 73: 166-171, 1989).
  • Fibrinopeptides A and B can be released from recombinant fibrinogen (Bolyard and Lord, Blood, 73:1202-1206, 1989; Lord and Fowlkes. Blood, 73: 166-171. 1989).
  • Eukaryotic cells carrying appropriate expression plasmids encoding individual fibrinogen chains have been shown to synthesize the encoded fibrinogen chains and to result in the intracellular formation of dimeric chain molecules, e.g. A ⁇ 2 , B ⁇ 2 or ⁇ 2 dimers (Roy et al., J. Biol. Chem., 265:6389-6393, 1990; Zhang and Redman, J. Biol. Chem. 261:21121-21132, 1992).
  • Fibrinogen is naturally synthesized by liver, and megakaryocyte cells and transformed liver cells maintained in culture are able to continue fibrinogen synthesis and secretion (See Otto et al., J. Cell. Biol. 105: 1067-1072, 1987; Yu et al., Thromb. Res. 46:281-293, 1987; Alving et al., Arch. Biochem. Biophys. 217:19, 1982).
  • One such cell line is the Hep G2 cells (Drs. Knowles and Aden, Wister Institute, Philadelphia).
  • This line synthesizes an excess of Act- and ⁇ -chains over the Bb-chains resulting in nonproductive dimeric complexes of A ⁇ - and ⁇ -chains (e.g., A ⁇ 2 ⁇ 2).
  • the introduction of an additional expression vector encoding B ⁇ -chains resulted in the formation of trimeric complexes (A ⁇ B ⁇ ) which adopt the correct folding and intrachain disulfide bonding patterns (Roy et al.. J. Biol. Chem., 265:6389-6393, 1990).
  • the mechanism of this folding is unknown and may involve ancillary proteins and enzymes (Roy et al., J. Biol. Chem. , 267:23151 -23158, 1992).
  • Eukaryotic cells known to be capable of assembling and secreting recombinant fibrinogen include baby hamster kidney cells (BHK), COS cells and Chinese hamster ovary cells (CHO) (Roy et al., J. Biol. Chem. 266:4758-4763, 1991 ; Hartwig and Danishefsky, J. Biol. Chem. 266:6578-6585, 1991 ; Farrell et al., Biochemistry 30:9414- 9420, 1991).
  • Intact functional fibrinogen secreted by stably transformed eukaryotic cells results in the accumulation of fibrinogen levels of around 1-2 ⁇ g/ml.
  • Methods are known for increasing the output of recombinant proteins from transfected cells like CHO cells such that the expression levels can approach a thousand fold the basal secretory level.
  • non-replicating forms of the human immunodeficiency virus are being engineered for use as gene therapy vectors that allow for the incorporation of the genetic material into genomic DNA.
  • Such vectors must maintain the genetic tools by which to facilitate genomic incorporation, but must lack enough of the gene products that create infectivity, such that in this case for AIDS there is no chance that recombination events will regenerate an infective particle. See, Naldini et al., "Lentiviral Vectors" in Development of Human Gene Therapy, Cold Spring Harbor Laboratory Press, 1998, pp. 47-60.
  • nucleic acid-based vaccines for example, an immune response is desirable, as can be a process by which expression of the transforming gene attenuates so that production of the immuno-stimulant attenuates over time.
  • Viral vectors have also been subject to engineering to change their target cell preference, for instance by binding or incorporating antibodies. For instance, Valsesia- Wittmann et al. modified the cell-surface binding characteristics of avian leukosis virus. J. Virol.
  • Erythropoietin which of course binds its cognate receptor, has been incorporated into Moloney murine leukemia virus (Mo-MLV). Kasahara et al., Science 266: 1373-1376, 1994. A tumor-targeting single-chain antibody has been incorporated into spleen necrosis virus. Chu and Dornburg, J. Virol. 69: 2659- 2663. 1995. HIV envelop protein has been incorporated into murine leukemia viral vectors. Mammamo et al., J Virol. 71 : 3341-3345, 1997.
  • nucleic acid can be delivered successfully without the use of viral vectors.
  • an early-developed method for increasing transfection efficiency was to use calcium phosphate-precipitated nucleic acid.
  • the transfection potential of nucleic acid is increased by compacting it with polycationic polymers such as DEAE dextran (Veheri et al., Virology 27: 434-436, 1965), polylysine (Wu et al., J. Biol. Chem.
  • Enhancers of nucleic acid uptake include erodable microspheres (Mathiowitz et al., Nature 386: 410-412, 1997) and polyvinyl pyrrolidone (Mumper et al., Pharm. Res. 13: 701-709, 1996).
  • enhancers include cationic liposomes into which the nucleic acid is incorporated. Feigner et al., 1987; Feigner and Ringold, 1989. Such liposomes, or "lipoplexes,” are believed to insert the nucleic acid into a target cell by a membrane fusion mechanism.
  • DOTMA N[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium
  • cationic lipid formulations include LipofectinTM, a 1 : 1 (w/w) liposome formulation of the cationic lipid ⁇ -[l-(2,3-dioleyloxy)propyl]- ⁇ , ⁇ , ⁇ - trimethylammonium chloride (DOTMA) and dioleoyl phosphatidylethanolamine (DOPE), LipofectAMINETM, a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-l- propanaminiumtrifluoroacetate (DOSPA) and the neutral lipid dioleoyl phosphatidylethanolamine (DOPE) in membrane-filtered water, and LipofectACETM, a 1 :2.5 (w/w) liposome formulation of the cationic lipid dimethyl dioctadecylammonium bromide (DDAB
  • gene transfer can also be achieved without such adjuvants.
  • Targeting techniques can also be employed which bind or affix targeting molecules to the nucleic acid or nucleic acid complex to be used for transfection. Cotton and Wagner, "Receptor-mediated Gene Delivery Strategies,” in Development of Human Gene Therapy, Cold Spring Harbor Laboratory Press, 1998, pp. 261-277.
  • the nucleic acid sought to be introduced into cells will often include, in addition to the portion conveying the primary genetic characteristic of interest, a portion encoding a substance that is itself, or gives rise to, a molecule that is readily detectable.
  • This "reporter" molecule serves as a surrogate for determining or estimating success in introducing the primary genetic characteristic.
  • a portion of the nucleic acid can encode a substance required for the cells to survive in the face of an appropriate challenge.
  • the nucleic acid can be single or double-stranded, though non-virally mediated techniques that seek to express a portion of the nucleic acid will typically use double-stranded nucleic acid.
  • factor XIII a a inhibitors such as heavy metals (such as mercury), thiomerosal ⁇ [(o-carboxyphenyl) thiojethyl mercury sodium salt ⁇ , inhibitory antibodies, or calcium chelators (since calcium is a necessary cofactor for the enzyme).
  • heavy metals such as mercury
  • thiomerosal ⁇ [(o-carboxyphenyl) thiojethyl mercury sodium salt ⁇ inhibitory antibodies
  • calcium chelators since calcium is a necessary cofactor for the enzyme.
  • Calcium chelators include, but are not limited to, EGTA (ethylenglycolbis-(2- aminoethylether)tetra-acetic acid), and the like.
  • the converting enzyme is batroxobin. ("Btx"), a proteinase from the snake venom of snakes of the genus Bothrops, used at a concentration of about 0.1 ⁇ g/ml to about 100 ⁇ g/ml, preferably to a concentration of about 0.5 ⁇ g/ml to about 50 ⁇ g/ml.
  • Btx a proteinase from the snake venom of snakes of the genus Bothrops
  • Other proteinases of appropriate specificity can also be used.
  • Snake venom proteinases are particularly suitable, including without limitation the venom enzymes from Agkistrodon acutus, Agkistrodon contortrix contortrix, Agkistrodon halys pallas, Agkistrodon (Calloselasma) rhodostoma, Bothrops asper, Bothrops atrox, Bothrops insularis, Bothrops jararaca. Bothrops Moojeni, Lachesis muta muta, Crotalus adamanteus, Crotalus durissus terrificus, Tr inter esurus flavorviridis, Trimeresurus gramineus and Bitis gabonica.
  • the fibrinogen-converting enzyme is favorably coupled to a converting enzyme binding partner which is used in an affinity procedure to reduce the concentration of the enzyme in a preparation.
  • the converting enzyme binding partner is biotin. a member of the biotin-avidin binding pair, a pair of molecules that bind with extremely high affinity.
  • An amino acid sequence for avidin is described in Dayhoff, Atlas of Protein Sequence, Vol. 5, National Biomedical Research Foundation, Washington, DC. 1972 (see also, DeLange and Huang, J. Biol. Chem. 246: 698-709, 1971).
  • an amino acid sequence for Streptavidin is described in Argarana et al., Nucl. Acid Res. 14:1871-1882, 1986.
  • Nucleic acid sequences are available, for example, as follows: (1) chicken mRNA for avidin, Gene Bank Ace. No. X05343, Gore et al., Nucl. Acid Res. 15: 3595-3606, 1987; (2) chicken, strain White Leghorn gene for avidin. Gene Bank Ace. No. L27818 (3) streptavidin from Strep, avidinii, Gene Bank Ace. No. X03591 , Argarana et al., Nucl. Acid Res. 14: 1871-1882, 1986; (4) synthetic gene for streptavidin from Strep, avidinii, Gene Bank Ace. No. A00743, Edwards, WO89/03422; and (5) synthetic gene for streptavidin, Gene Bank Ace. No. X65082, Thompson et al., Gene 136: 243-246, 1993.
  • Avidin and Streptavidin are preferably used in a tetrameric form, although monomers can be used.
  • Other binding pairs that bind with high affinity include an antibody specific for a polypeptide or other molecule, any polypeptide to which an antibody is available or can be prepared, thioredoxin, which binds phenylarsine oxide (expression vectors include, for example, the thioredoxin fusion protein vector pTrxFus available from Invitrogen, Carlsbad, CA), poly-His sequences that bind to divalent cations such as nickel II (expression vectors include, for example, the pThioHis vectors A, B and C available from Invitrogen), glutathione-S-transferase vectors that bind to glutathione (vector for example available from Pharmacia Biotech, Piscataway, NJ).
  • fibrin monomer is recovered from the fibrin clot.
  • fibrin monomer is recovered, for example, by adding a solubilizing agent to the fibrin clot.
  • solubilizing agents can include, for example, acid solutions such as aqueous solutions having pH of about 5 or less, or chaotropic agents, such as urea, sodium bromide, guanidine hydrochloride, potassium cyanide, potassium iodide or potassium bromide.
  • the solubilizing agents can be used at near the minimum concentration effective to maintain fibrin monomer (i.e., a fibrin-solubilizing effective amount).
  • fibrin monomer i.e., a fibrin-solubilizing effective amount.
  • a number of conditions for forming fibrin monomer are described in Edwardson et al., European Patent Application No. EP 592.242.
  • a solid material having bound thereto a second binding partner which is the complementary binding partner to the converting enzyme binding partner, is then added the fibrin monomer preparation to bind any converting enzyme as may continue to be found in the preparation.
  • the solids which, depending on the protocol used, can include the solid material or any residual fibrin clot material, is then removed, for instance by filtration or centrifugation.
  • the processed material can be stored in liquid form, for instance at about 4°C or less, in frozen form, or as a dried form such as a lyophilizate.
  • Lyophilizates are formed by standard methods. These lyophilizates are generally reconstituted in purified water or in a buffered aqueous solution.
  • the same solution composition of solubilizing agent previously used in the process can be used to reconstitute the lyophilizate.
  • an aqueous solution which either (a) lacks a solubilizing agent or (b) is capable of reversing any solubilizing conditions carried in the lyophilizate, is employed.
  • the fibrin monomer and a non- enzymatic polymerizing agent can be mixed together.
  • the polymerizing agent is any reagent effective to reverse the conditions that prevent the polymerization of fibrin monomer.
  • the polymerizing agent can be a basic solution, such as, without limitation, a solution of HEPES (N-[2-hydroxyethyl)piperazine-N'- [ethanesulfonic acid]), sodium hydroxide, potassium hydroxide, calcium hydroxide, bicarbonate buffers such as sodium bicarbonate and potassium bicarbonate, tri-metal salts of citric acid, salts of acetic acid and salts of sulfuric acid.
  • HEPES N-[2-hydroxyethyl)piperazine-N'- [ethanesulfonic acid]
  • sodium hydroxide sodium hydroxide
  • potassium hydroxide calcium hydroxide
  • bicarbonate buffers such as sodium bicarbonate and potassium bicarbonate
  • tri-metal salts of citric acid salts of acetic acid and salts of sulfuric acid.
  • Preferred alkaline buffers include: carbonate/bicarbonate; glycine; bis hydroxeythylaminoethane sulphonic acid (BES); hydroxyethylpiperazine propane sulphonic acid (EPPS); Tricine; morpholino propane sulphonic acid (MOPS); trishydroxymethyl aminoethane sulphonic acid (TES); cyclohexylaminoethane sulphonic acid (CHES); trishydroxymethyl aminoethane sulphonic acid (TES).
  • the amount of alkaline buffer that is utilized should be enough to allow polymerization of the fibrin. It is preferred that about 10 parts to about one part of composition comprising fibrin monomer be mixed with about 1 part alkaline buffer.
  • Such ratio be about 9: 1.
  • the preferred ratio depends on the buffer, its concentration and pH, and the desired concentration of the fibrin polymer. Where acidic pH is used as the solubilizing agent, the fibrin solubilization can occur in the presence of calcium ions, such as at a concentration of about 20 mM.
  • three streams of aqueous preparations are mixed to initiate a rapid clot formation process.
  • These preparations can be, for example, a fibrin monomer preparation, a composition comprising the nucleic acid for transforming or transfecting cells ("transforming composition" or "TC"), and a non-enzymatic polymerizing agent.
  • the preparations are fibrinogen, a fibrinogen-converting enzyme and the TC.
  • the sealant mixture is generally formed either during the process by which the sealant is applied to its recipient surface, or within a few minutes prior to application. Generally, the sealant mixture remains conveniently pliable for about 30 seconds or less.
  • the three streams are sprayed so that they converge and mix.
  • Suitable spray heads are described in US Patent Nos. 5,605,541, 5,376,079, and 5,520,658 and PCT Application 97/20585.
  • additional spray heads can be aligned to deliver other solutions to the site of delivery.
  • the spray head delivers two concentric rings of sprayed solution or suspension, and uses gas outlets to shape and merge the streams
  • a second such spray head can be used to deliver a third solution.
  • the TC can, where appropriate, be incorporated into one of the other two preparations.
  • the TC can be mixed with the sealant after the polymerization process has been initiated but while the composition remains pliable.
  • the TC can be applied to cells or tissue, and the sealant can be applied to fix the TC in place.
  • Such a subsequently applied sealant would preferably be applied concurrent with or soon after the process which polymerizes the sealant is initiated.
  • Other types of fibrin sealant useful in the invention are described in, for example: Wadtrom, U.S. Patent 5,631,01 1 ; Cochrum. U.S. Patent 5,510,102; Pines et al., U.S.
  • Patent 5,330,974 Matras, J Oral Maxillofacial Surgery 13: 605-61 1, 1985; and Brennan, Blood Reviews 5: 240-244, 1991.
  • Another device for spraying a fibrin sealant is described, for example, in Avoy, U.S. Patent 4,902,281.
  • fibrin ancillary factors such as factor XIII or factor XIII a and thrombin.
  • fibrin ancillary factors such as factor XIII or factor XIII a and thrombin.
  • purification techniques are used that isolate fibrin via the reversible formation of a fibrin polymer, it is believed that the fibrin polymer has affinity for a number of such ancillary factors, such that the isolated product will retain these factors.
  • the present invention can be used for treating any animal having a fibrin-based system for controlling bleeding, but is preferably used for treating mammals, most preferably humans.
  • O cell precursor of a more specialized cell type is a cell, typically referred to as a “stem” cell or a “pluripotent” cell, which has the potential to, but has not yet, differentiated into a more specialized cell.
  • fibrinogen i.e., desAA- fibrin
  • fibrin II i.e., desAAdesBB fibrin
  • des BB fibrin that can polymerize to form a precipitate of fibrin polymer.
  • the derivatives are typically created by cleaving the A or
  • a form of fibrin monomer is an engineered version of fibrin, or "fibrin analog/' which will not self-polymerize, but will polymerize with another fibrin-related molecule such as fibrinogen.
  • fibrinogen an engineered fibrin
  • Such an engineered fibrin is described in Cederholm- Williams et al., "Recombinant Fibrin Chains, Fibrin and Fibrin-Homologs," PCT Application No. PCT/US95/05527, filed May 2, 1995.
  • O fibrin chain precursor Precursor of a fibrin ⁇ -chain or ⁇ -chain containing a N-terminal peptide that can be cleaved to yield the fibrin chain effective in a fibrin to allow polymerization.
  • O fibrin clot-forming effective amount An effective amount of clot-forming fibrin is that quantity or concentration (if in a liquid form) of a fibrin (for example fibrin monomer) which forms sufficient clot material to be of utilized as a fibrin sealant.
  • O fibrin monomer O fibrin monomer.
  • Fibrin monomer is fibrin that is held in soluble form and prevented from clotting, for instance by the presence of a polymerization inhibitor such as acidic pH or a chaotropic agent or by being kept in a form which prevents polymerization, such as a sufficiently dehydrated form or a frozen form.
  • a polymerization inhibitor such as acidic pH or a chaotropic agent
  • Fibrin molecules in the absence of conditions that prevent polymerization of fibrin monomer, interact noncovalently to form polymers, here termed "fibrin polymers", which - when sufficient mass is achieved - form a visible adherent precipitate with clot-like properties.
  • fibrin polymers By the action of factor XIII a , fibrin polymer can be covalently crosslinked. Prior to the crosslinking action of factor XIII a , fibrin polymer can be reversibly converted to fibrin monomer. Even when some initial such crosslinking has occurred, it is believed that fibrin polymer can be reversibly converted to fibrin monomer. O fibrin precursor.
  • a Precursor of fibrin comprises one or more fibrin chain precursors which must be processed to yield a form of fibrin that polymerizes with corresponding fibrin molecules.
  • a fibrin precursor contains one or more leader peptides on its constituent chains. The leader peptide(s) can be processed in vivo or in vitro from the fibrin precursor to yield fibrin. O gene therapy.
  • gene therapy includes any intervention in an animal (preferably a mammal, more preferably a human) that (i) causes a cell in the animal to express (as RNA or protein) a recombinant nucleic acid, whether such expression is transient or stable, or (ii) causes a change in the cell's genome, such as an insertion, that changes the cell's pattern of gene expression.
  • gene therapy includes uses of nucleic acid-based vaccines. O high affinity binding. High affinity binding between a first substance and a second substance is binding of sufficient avidity to allow for the first or second substance to be used as an affinity ligand for the isolation of the other substance.
  • high affinity binding is reflected in an association constant of about 10 5 M “1 or more, preferably 10 6 M “ ' or more, yet more preferably 10 7 M '1 or more.
  • the conjunction "or” is used to express that at least one of the recited alternatives linked by or is applicable in a given context and to include the conjunctive sense , joining two or more of the recited alternatives. In other words, unless the context indicates a contrary meaning, "or” includes the meaning sometimes expressed as "and/or.” O Polynucleotide or nucleic acid.
  • polynucleotide(s) or nucleic acid(s) generally refer to any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA.
  • Polynucleotide(s) include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions.
  • polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • polynucleotide(s) also includes DNAs or RNAs as described above that contain one or more modified bases.
  • DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleotide(s)” as that term is intended herein.
  • DNAs or RNAs comprising unusual bases, such as inosine. or modified bases, such as tritylated bases, to name just two examples are polynucleotides as the term is used herein.
  • polynucleotide(s) as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)” also embraces short polynucleotides often referred to as oligonucleotide(s).
  • a cell is transformed if a nucleic acid is recombinantly introduced into it or its ancestor so as to temporarily or stably (1) cause the cell to express a polypeptide or RNA in an amount not otherwise expressed by the cell or (2) interfere with the translation or transcription of a nucleic acid normally found in the cell.
  • O transforming composition is a composition containing a gene therapy effective amount of a nucleic acid.

Abstract

présentée à titre d'exemple, cette technique de transformation cellulaire consiste: à appliquer une quantité efficace d'un acide nucléique de transformation vers une cellule, à appliquer un gel de fibrine à la cellule de façon à piéger une quantité efficace d'acide nucléique de transformation, et à transformer la cellule avec cet acide nucléique. Dans un aspect de cette invention, on applique l'acide nucléique sous forme de mélange avec une composition de fibrine ou fibrinogène qui forme le gel de fibrine.
PCT/US1999/013508 1999-06-16 1999-06-16 Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique WO2000077227A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/US1999/013508 WO2000077227A1 (fr) 1999-06-16 1999-06-16 Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique
JP2001503669A JP2003502047A (ja) 1999-06-16 1999-06-16 遺伝子治療のためのトランスフェクション／形質転換ビヒクルとしてのフィブリンシーラント
EP99935322A EP1208212A4 (fr) 1999-06-16 1999-06-16 Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique
CA002375346A CA2375346A1 (fr) 1999-06-16 1999-06-16 Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/013508 WO2000077227A1 (fr) 1999-06-16 1999-06-16 Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique

Publications (1)

Publication Number Publication Date
WO2000077227A1 true WO2000077227A1 (fr) 2000-12-21

Family

ID=22272977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013508 WO2000077227A1 (fr) 1999-06-16 1999-06-16 Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique

Country Status (4)

Country Link
EP (1) EP1208212A4 (fr)
JP (1) JP2003502047A (fr)
CA (1) CA2375346A1 (fr)
WO (1) WO2000077227A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046017A2 (fr) * 2004-10-26 2006-05-04 The Secretary Of State For Environment, Food & Rural Affairs Vaccin et acides nucleiques
EP2310411B1 (fr) 2008-07-09 2016-05-11 ProFibrix BV Fibrinogène recombinant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5750657A (en) * 1992-10-08 1998-05-12 Bristol-Myers Squibb Company Methods and compositions using fibrin monomer to make a fibrin sealant
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804249A2 (fr) * 1994-03-15 1997-11-05 Brown University Research Foundation Systeme de liberation de genes polymeres

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5750657A (en) * 1992-10-08 1998-05-12 Bristol-Myers Squibb Company Methods and compositions using fibrin monomer to make a fibrin sealant
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1208212A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046017A2 (fr) * 2004-10-26 2006-05-04 The Secretary Of State For Environment, Food & Rural Affairs Vaccin et acides nucleiques
WO2006046017A3 (fr) * 2004-10-26 2006-09-14 Al Affairs The Sec Dep For Env Vaccin et acides nucleiques
EP2310411B1 (fr) 2008-07-09 2016-05-11 ProFibrix BV Fibrinogène recombinant
US10562956B2 (en) 2008-07-09 2020-02-18 Mallinckrodt Pharma Ip Trading D.A.C. Recombinant fibrinogen

Also Published As

Publication number Publication date
EP1208212A1 (fr) 2002-05-29
EP1208212A4 (fr) 2007-05-02
CA2375346A1 (fr) 2000-12-21
JP2003502047A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
US20020064517A1 (en) Fibrin sealant as a transfection/transformation vehicle for gene therapy
JP4954370B2 (ja) 共役不飽和基に対する求核付加反応によって作製される生体適合材料
Kong et al. Design of biodegradable hydrogel for the local and sustained delivery of angiogenic plasmid DNA
JP5025059B2 (ja) 核酸を細胞に導入するための配合剤
L Santos et al. Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration
US5817303A (en) Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
US20100159512A1 (en) Method for the preparation of recombinant human thrombin and fibrinogen
RU2503464C2 (ru) Биогель
KR102410065B1 (ko) 피브리노겐-결합 펩타이드를 포함하는 펩타이드 덴드리머
US20080317761A1 (en) Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
US6492494B1 (en) Method of making a fibrin sealant comprising alpha-2-antiplasmin
US20120156284A1 (en) Enhanced biological autologous tissue adhesive composition and methods of preparation and use
EP1208212A1 (fr) Materiau d'obturation a base de fibrine utilise comme vehicule de transfection/transformation destine a la therapie genique
JP2002058485A (ja) コラーゲン結合性を有する骨形成促進融合蛋白質
JP2001526027A (ja) フィブリノーゲン変換酵素ハイブリド
EP0698107A1 (fr) Therapy genique s'appliquant a l'hemophilie
JPH0646875A (ja) 血液凝固阻害ペプチドの製造法
Gustafson Silk-elastinlike protein polymers for adenoviral cancer gene therapy
JP2001517201A (ja) 溶解性ペプチド

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2375346

Country of ref document: CA

Ref country code: CA

Ref document number: 2375346

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 503669

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999935322

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999935322

Country of ref document: EP